Sign in Subscribe
Securities law

Investigation into PepGen Inc. Securities Class Action Filed by Lead Plaintiff Deadline

Strategic Insights

— 1 min read

PepGen Inc. and its executives are being investigated by Faruqi & Faruqi LLP for potential claims related to false and misleading statements regarding the effectiveness and safety of PGN-EDO51, the CONNECT2 study, and clinical, regulatory, and commercial prospects of the company. The investigation focuses on the company's statements from July 30, 2024, to January 29, 2025, which allegedly misled investors about the progress and prospects of PGN-EDO51 and the CONNECT2 study. The law firm is seeking a lead plaintiff to represent investors in a federal securities class action lawsuit against PepGen Inc.

Key Takeaways:

  • Faruqi & Faruqi is investigating potential claims against PepGen Inc. and its executives for allegedly making false and/or misleading statements and/or failing to disclose information about PGN-EDO51 and the CONNECT2 study.
  • The complaint alleges that the company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that PGN-EDO51 was less effective and safe than believed, and that the CONNECT2 study was dangerous or otherwise deficient for FDA approval.
  • PepGen released positive clinical data from the first dose cohort of PGN-EDO51 on July 30, 2024, but subsequent analysis showed disappointing results, causing the stock price to fall $5.55 per share, or 32.69%, on July 31, 2024.
  • The FDA issued a clinical hold notice on December 16, 2024, regarding the IND application for the CONNECT2 study, citing concerns about risks to patients in the study and/or other deficiencies associated with the study.
  • PepGen issued a press release on January 29, 2025, providing updates on safety concerns in the CONNECT1 study and fears regarding the CONNECT2 study, further impacting the stock price.
  • See www.faruqilaw.com for more information about the firm's background and experience.

Statistics:

  • PepGen's stock price fell $5.55 per share, or 32.69%, on July 31, 2024, after disappointing results from the first dose cohort of PGN-EDO51.
  • The stock price fell $0.17 per share, or 3.63%, on December 16, 2024, after the FDA's clinical hold notice regarding the CONNECT2 study.
  • The stock price was further impacted on January 29, 2025, by updates on safety concerns in the CONNECT1 study and concerns regarding the CONNECT2 study.

Sources:

  • Faruqi & Faruqi LLP's News Release (August 11, 2025)
  • www.faruqilaw.com

Read more